[1] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609−1678. doi: 10.1093/europace/euw295 [2] Go AS, Reynolds K, Yang J, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM Study. JAMA Cardiol 2018; 3: 601−608. doi: 10.1001/jamacardio.2018.1176 [3] Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018; 15: e190−e252. doi: 10.1016/j.hrthm.2017.10.035 [4] Rottner L, Bellmann B, Lin T, et al. Catheter ablation of atrial fibrillation: state of the art and future perspectives. Cardiol Ther 2020; 9: 45−58. doi: 10.1007/s40119-019-00158-2 [5] Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA Randomized Clinical Trial. JAMA 2019; 321: 1261−1274. doi: 10.1001/jama.2019.0693 [6] Saglietto A, De Ponti R, Di Biase L, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta-analysis. J Cardiovasc Electrophysiol 2020; 31: 1040−1047. doi: 10.1111/jce.14429 [7] [8] Cai L, Yin Y, Ling Z, et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int J Cardiol 2013; 164: 82−87. doi: 10.1016/j.ijcard.2011.06.094 [9] Zink MD, Chua W, Zeemering S, et al. Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace 2020; 22: 1337−1344. doi: 10.1093/europace/euaa132 [10] [11] Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol 2015; 66: 985−996. doi: 10.1016/j.jacc.2015.06.488 [12] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1−e76. doi: 10.1016/j.jacc.2014.03.022 [13] Deisenhofer I, Estner H, Zrenner B, et al. Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation: incidence, electrophysiological characteristics, and results of radiofrequency ablation. Europace 2006; 8: 573−582. doi: 10.1093/europace/eul077 [14] Zhou D, Yang K, Hu J, et al. Noncoding RNAs in Atrial Fibrillation: Current Status and Prospect. J Cardiov asc Pharmacol 2020; 75: 10−17. doi: 10.1097/FJC.0000000000000762 [15] Wilusz JE. A 360° view of circular RNAs: From biogenesis to functions. Wiley Interdiscip Rev RNA 2018; 9: e1478. doi: 10.1002/wrna.1478 [16] Maass PG, Glažar P, Memczak S, et al. A map of human circular RNAs in clinically relevant tissues. J Mol Med (Berl) 2017; 95: 1179−1189. doi: 10.1007/s00109-017-1582-9 [17] Altesha MA, Ni T, Khan A, et al. Circular RNA in cardiovascular disease. J Cell Physiol 2019; 234: 5588−5600. doi: 10.1002/jcp.27384 [18] Wu N, Li J, Chen X, et al. Identification of long non-coding rna and circular RNA Expression Profiles in Atrial Fibrillation. Heart Lung Circ 2020; 29: e157−e167. doi: 10.1016/j.hlc.2019.10.018 [19]

Sun H, Zhang J, Shao Y. Integrative analysis reveals essential mRNA, long non-coding RNA (lncRNA), and circular RNA (circRNA) in paroxysmal and persistent atrial fibrillation patients. Anatol J Cardiol 2021; 25: 414−428.

[20] Zhu X, Tang X, Chong H, et al. Expression profiles of circular RNA in human atrial fibrillation with valvular heart diseases. Front Cardiovasc Med 2020; 7: 597932. doi: 10.3389/fcvm.2020.597932 [21]

Hu M, Wei X, Li M, et al. Circular RNA expression profiles of persistent atrial fibrillation in patients with rheumatic heart disease. Anatol J Cardiol 2019; 21: 2−10.

[22]

Zhang Y, Ke X, Liu J, et al. Characterization of circRNAassociated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Mol Med Rep 2019; 19: 638−650.

[23] Zhu X, Wang Y, Mo R, et al. Left atrial appendage circular RNAs are new predictors of atrial fibrillation recurrence after surgical ablation in valvular atrial fibrillation patients. Heart Surg Forum 2021; 24: E968−E976. doi: 10.1532/hsf.4125 [24]

Chen LQ, Yi CL, Liu DC, et al. Hsa_circ_0041103 induces proliferation, migration and invasion in bladder cancer via the miR-107/FOXK1 axis. Eur Rev Med Pharmacol Sci 2021; 25: 1282−1290.

[25]

Shi X, Wallis AM, Gerard RD, et al. Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2. J Cell Sci 2012; 125: 5329−5337.

[26] Wang Y, Liu G, Sun S, et al. miR-1294 alleviates epithelial-mesenchymal transition by repressing FOXK1 in gastric cancer. Genes Genomics 2020; 42: 217−224. doi: 10.1007/s13258-019-00899-3 [27] König E, Volpato CB, Motta BM, et al. Exploring digenic inheritance in arrhythmogenic cardiomyopathy. BMC Med Genet 2017; 18: 145. doi: 10.1186/s12881-017-0503-7 [28] Cai Z, Wang Y, Yu W, et al. hnulp1, a basic helix-loop-helix protein with a novel transcriptional repressive domain, inhibits transcriptional activity of serum response factor. Biochem Biophys Res Commun 2006; 343: 973−981. doi: 10.1016/j.bbrc.2006.02.187 [29]

Lu Y, Hou S, Huang D, et al. Expression profile analysis of circulating microRNAs and their effects on ion channels in Chinese atrial fibrillation patients. Int J Clin Exp Med 2015; 8: 845−853.

[30] Mun D, Kim H, Kang JY, et al. Expression of miRNAs in circulating exosomes derived from patients with persistent atrial fibrillation. FASEB J 2019; 33: 5979−5989. doi: 10.1096/fj.201801758R